Zinc Acetate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Zinc Acetate
- Zinc Acetate: From Wilson Disease and Dermatologic Conditions to Severe Nonproliferative Diabetic Retinopathy
Zinc Acetate: From Wilson Disease and Dermatologic Conditions to Severe Nonproliferative Diabetic Retinopathy
One-Sentence Summary
Zinc acetate is a zinc salt used for conditions such as Wilson disease, dermatitis, burns and iron metabolism disorders. The TxGNN model predicts it may be effective for severe nonproliferative diabetic retinopathy, but there are currently 0 clinical trials and 0 publications supporting this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Wilson disease, dermatitis, exanthem, otitis externa, hemorrhoid, burn, hereditary hemochromatosis and others (from the knowledge graph; the Singapore licences list no approved indication text) |
| Predicted New Indication | Severe nonproliferative diabetic retinopathy |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for this report. Zinc is an essential trace element that serves as a cofactor for many enzymes, including superoxide dismutase (an antioxidant enzyme), and it plays roles in immune function, wound healing and epithelial integrity. These are the likely reasons for its existing dermatologic and tissue-repair indications.
A possible link to diabetic retinopathy is zinc's antioxidant and anti-inflammatory activity in diabetic microvascular disease and in retinal metabolism. This link is speculative: the data compiled for this report contain no trials or publications to support it. The related prediction for diabetic retinopathy (score 99.92%) carries the same signal and is not independent evidence.
Other top predictions (bronchitis, acrodermatitis chronica atrophicans, dermatomyositis variants, acne keloid, hydroa vacciniforme, childhood interstitial lung disease, urinary tract infection) also have no supporting clinical evidence. Several likely reflect dermatologic or autoimmune similarity in the knowledge graph rather than a true mechanism. For bronchitis, the only publication is a zinc oxide nanoparticle materials study. For urinary tract infection, the only publication is a 1999 study of zinc supplementation and infections in sickle cell disease, which is indirect evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for severe nonproliferative diabetic retinopathy.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16734P | NUTRIFLEX® OMEGA SPECIAL B. BRAUN EMULSION FOR INFUSION | Injection, emulsion | Not stated |
| SIN15468P | NUTRIFLEX® OMEGA PLUS EMULSION FOR INFUSION | Injection, emulsion | Not stated |
| SIN15469P | NUTRIFLEX® OMEGA SPECIAL EMULSION FOR INFUSION | Injection, emulsion | Not stated |
All three are single-ingredient registrations by B. Braun Melsungen AG and are valid. They are parenteral nutrition emulsions for infusion, not oral or topical zinc acetate products. No ophthalmic route is available.
Safety Considerations
- Contraindications (knowledge graph, not label text): Porphyria, inherited porphyria and porphyrin metabolism disease.
- Drug Interactions: 100 interactions were identified. Examples include:
- Moderate: alendronic acid, risedronic acid, ibandronate, tetracycline, baloxavir marboxil. These are likely chelation or absorption interactions, so dosing should be separated.
- Minor: abatacept, adalimumab, hydrocortisone, dexamethasone, betamethasone, triamcinolone, azathioprine, baricitinib, belimumab and other immunomodulators.
Please refer to the package insert for further safety information, including warnings and label contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high (99.97%), but it is a model output only. No clinical trials or publications support zinc acetate in severe nonproliferative diabetic retinopathy, and the Singapore products are infusion emulsions with no suitable route for this use. Label-based safety data are also missing.
To proceed, the following is needed:
- Package insert warnings and contraindications from the HSA (a blocking gap for safety screening)
- Mechanism of action data (for example from DrugBank) to support the retinal link
- A systematic literature and trial search on zinc and diabetic retinopathy, including preclinical and observational studies
- Route and formulation assessment (oral zinc acetate vs. the available infusion products)
- Review of the zinc-porphyria contraindication signal and the chelation interactions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.